Author:
Bell Blossom,Swainston Katherine
Abstract
Abstract
Purpose
Despite a haematopoietic stem cell transplant (HSCT) being a potentially curative treatment option for malignant and non-malignant disorders, patients may develop complex physical and psychological post-transplant complications. Consequently, transplant centres remain responsible for patients’ life-long monitoring and screening practices. We sought to describe how HSCT survivors experience long-term follow-up (LTFU) monitoring clinics in England.
Method
A qualitative approach was adopted with data collected from written accounts. Seventeen transplant recipients were recruited from across England, and the data was analysed using thematic analysis.
Results
Data analysis elicited four themes: Transfer to LTFU care: ‘will there be a change in my care, or will appointments just become less frequent?’; Care Coordination: ‘it is good to know I am still in the system’; Relationship continuity: ‘a good knowledge of me, my health and what is important to me’; and Late-effects Screening: ‘there was not much information about what to expect or be aware of’.
Conclusions
HSCT survivors in England experience uncertainty and lack of information regarding the transfer from acute to long-term care and clinic screening practices. However, patients gain reassurance from remaining on a healthcare pathway and maintaining relationships with healthcare professionals.
Implications for cancer survivors
HSCT recipients entering LTFU monitoring clinics are a growing population of cancer survivors. Understanding and acknowledging this cohort of patients’ needs may inform the development of tailored support to help patients navigate the complicated healthcare pathway.
Publisher
Springer Science and Business Media LLC
Subject
Oncology (nursing),Oncology
Reference30 articles.
1. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Savani BN, Veys PA, Bredeson CN, Giralt SA, LeMaistre CF. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015. https://doi.org/10.1016/j.bbmt.2015.07.032.
2. Hatzimichael E, Tuthill M. Hematopoietic stem cell transplantation. Stem Cells Cloning: Adv Appl. 2010. https://doi.org/10.2147/SCCAA.S6815.
3. Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Cámara R, Corbacioglu S, Dolstra H, Duarte R, Glass B, Greco R, Lankester AC, Mohty M, Peffault de Latour R, Snowden JA, Yakoub-Agha I, Kröger N, European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021. https://doi.org/10.1038/s41409-021-01227-8.
4. British Society of Blood and Marrow Transplantation and Cellular Therapy. UK & ROI Transplant Activity Table by Disease. In: Annual activity. British Society of Blood and Marrow Transplantation and Cellular Therapy. 2020. https://bsbmtct.org/activity/2020/. Accessed 28 Oct 2022.
5. Maziarz RT. Overview of hematopoietic cell transplantation and cellular therapy. In: Maziarz RT, Slater SS, editors. Blood and marrow transplant handbook; comprehensive guide for patient care. 3rd ed. Switzerland: Springer Nature; 2021. p. 1–10.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献